KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Minority Interest (2016 - 2020)

Inovio Pharmaceuticals (INO) has disclosed Minority Interest for 11 consecutive years, with $96269.0 as the latest value for Q3 2020.

  • Quarterly Minority Interest fell 96.03% to $96269.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $96269.0 through Sep 2020, down 96.03% year-over-year, with the annual reading at $2.0 million for FY2019, 1946.1% up from the prior year.
  • Minority Interest hit $96269.0 in Q3 2020 for Inovio Pharmaceuticals, roughly flat from $96269.0 in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $3.5 million in Q1 2020 to a low of $96269.0 in Q2 2016.
  • Historically, Minority Interest has averaged $807336.1 across 5 years, with a median of $96269.0 in 2016.
  • Biggest five-year swings in Minority Interest: surged 3075.24% in 2019 and later crashed 96.64% in 2020.
  • Year by year, Minority Interest stood at $96269.0 in 2016, then changed by 0.0% to $96269.0 in 2017, then changed by 0.0% to $96269.0 in 2018, then surged by 1946.1% to $2.0 million in 2019, then tumbled by 95.11% to $96269.0 in 2020.
  • Business Quant data shows Minority Interest for INO at $96269.0 in Q3 2020, $96269.0 in Q2 2020, and $3.5 million in Q1 2020.